3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
News 2026-09-29 08:31 UTC
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / / September 29, 2026…
News 2026-09-29 08:31 UTC
Jaguar Health said preliminary results from an ongoing open-label crofelemer study in adult SBS-IF patients will be presented at the American College of Gastroenterology Annual Scientific Meeting on Oct. 9-14, 2026. It also plans to report Phase 2 placebo-controlled trial results in adult Type 1 short bowel syndrome pa
News 2026-09-29 08:30 UTC
Jaguar Health (JAGX) says preliminary results from an open-label study in adult short bowel syndrome with intestinal failure (SBS-IF) using Crofelemer have been accepted for presentation at the annual American College of Gastroenterology meeting.